HCAT vs SRTS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.
SRTS exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY revenue decline of 62.20%. While the company maintains a strong liquidity position with a Current Ratio of 9.72 and negligible debt, these are offset by negative operating margins (-63.74%) and a consistent failure to meet earnings estimates. The recent short-term price appreciation contradicts the underlying financial decay and the bearish technical trend score of 0/100. Overall, the company is in a state of operational distress despite its clean balance sheet.
Compare Another Pair
Related Comparisons
HCAT vs SRTS: Head-to-Head Comparison
This page compares Health Catalyst, Inc. (HCAT) and Sensus Healthcare, Inc. (SRTS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.